Trial Profile
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL POETIC and ITCC.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary) ; Cyclophosphamide; Etoposide; Filgrastim; Filgrastim; Methotrexate
- Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Acronyms NECTAR
- 27 Jul 2020 This trial is completed in UK (Global End Date: 09 Nov 2015), according to European Clinical Trials Database record.
- 23 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 23 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.